Vertex’s IgA nephropathy drug halves a key kidney biomarker in Phase 3
Vertex reported Phase 3 data showing its IgA nephropathy drug reduced a key kidney-disease biomarker by about 50%, in a three-way race with Otsuka and Vera Therapeutics and signaling potential multi-billion-dollar annual sales.